ReST Therapeutics announces that Pr. John Krystal has joined its Scientific Advisory Board

ReST Therapeutics, clinical-stage biotech company developing breakthrough therapies to treat Alzheimer Disease (AD) and Post-Traumatic Stress Disorder (PTSD), today announced that Pr. John Krystal from Yale University has joined its Scientific Advisory Board.

Dr. Krystal is McNeil Professor and Chair of Psychiatry at Yale and Yale-New Haven Hospital. He studies the neurobiology and treatment of psychiatric disorders. His laboratory discovered the rapid antidepressant effects of ketamine. He directs the Yale Center for Clinical Investigation, Center for the Translational Neuroscience of Alcohol, and Neuroscience Division of the National Center for PTSD. He is a member of the National Academy of Medicine; Fellow of the American Association for the Advancement of Science; co-director of the Neuroscience Forum of the National Academies of Sciences, Engineering, and Medicine; editor of Biological Psychiatry; and co-founder of Freedom Biosciences.

“As we enter the clinical stage of our development with our CTA application this month, we are thrilled to be able to benefit from John’s pioneering experience in ketamine as we will refine the clinical development plan for our drug candidate FENM. declared Dr Gilles Rubinstenn, CEO & Co-Founder of ReST Therapeutics.